Literature DB >> 10572082

The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study.

B J Sanson1, P Simioni, D Tormene, M Moia, P W Friederich, M V Huisman, P Prandoni, A Bura, L Rejto, P Wells, P M Mannucci, A Girolami, H R Büller, M H Prins.   

Abstract

Deficiencies of antithrombin, protein C, and protein S are associated with an increased risk of venous thromboembolism. The objective of this study was to prospectively assess the incidence of venous thromboembolism in nontreated asymptomatic subjects with such a deficiency. We conducted a prospective cohort study in asymptomatic family members of unselected patients who presented with a venous thromboembolic event and who were found to have a deficiency of antithrombin, protein C, or protein S. No anticoagulant prophylaxis was given to the study participants, except during risk periods for venous thromboembolism. All venous thromboembolic events were diagnosed by objective diagnostic tests. A total of 208 individuals with a mean age of 37 years (range, 15 to 79) were included in the study. A total of 611 patient observation years was obtained. Nine venous thromboembolic events occurred, resulting in an annual incidence of 1.5% (95% confidence interval [CI], 0.7 to 2.8) for the 3 deficiencies combined. Five of these events occurred spontaneously, resulting in an annual incidence of spontaneous venous thromboembolism of 0.8% (95% CI, 0.3 to 1.9). For antithrombin, protein C, and protein S deficiencies separately, this figure was 1.6%, 1.0%, and 0.4%, respectively. Thirty-four subjects experienced a total of 40 risk periods during which 4 venous thromboembolic events occurred (10% per risk period). We conclude that the use of continuous anticoagulant prophylaxis seems not warranted in asymptomatic individuals with a deficiency of antithrombin, protein C, or protein S. During risk periods for venous thromboembolism, adequate anticoagulant prophylaxis is necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572082

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Risk factors for thromboembolism: pathophysiology and detection.

Authors:  S Solymoss
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

Review 2.  Issues concerning the laboratory investigation of inherited thrombophilia.

Authors:  Armando Tripodi
Journal:  Mol Diagn       Date:  2005

Review 3.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

Review 4.  The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?

Authors:  Elias Kfoury; Ali Taher; Said Saghieh; Zaher K Otrock; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2008-05-31       Impact factor: 2.316

5.  Haemostatic and fibrinolytic changes in obese subjects undergoing bariatric surgery: the effect of different surgical procedures.

Authors:  Roberta Lupoli; Marco Milone; Alessandro Di Minno; Paola Maietta; Pasquale Ambrosino; Mario Musella; Matteo N D Di Minno
Journal:  Blood Transfus       Date:  2014-12-16       Impact factor: 3.443

6.  Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.

Authors:  Seo-Won Choi; Bo-Bae Kim; Dong-Hyun Choi; Geon Park; Byung Chul Shin; Heesang Song; DongHun Kim; Dong-Min Kim
Journal:  Clin Cardiol       Date:  2017-08-14       Impact factor: 2.882

Review 7.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

9.  A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia.

Authors:  Philip S Wells; Martha L Louzada; Monica Taljaard; David R Anderson; Susan R Kahn; Nicole J Langlois; Julie Rutberg; Michael J Kovacs; Marc A Rodger
Journal:  J Genet Couns       Date:  2009-06-03       Impact factor: 2.537

10.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.